# A Study of MHB046C Injection in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06985355/  
OnCo record `nct06985355` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MHB046C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.

## Summary

A Study of MHB046C Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06985355 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants planned, started 2025-07-17 and due to reach its primary completion in 2029-05. Interventions recorded: MHB046C.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06985355
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MHB046C Injection in Patients With Advanced Solid Tumors
- Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06985355: https://clinicaltrials.gov/study/NCT06985355

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06985355.json